1. Home
  2. BLUW vs DRTS Comparison

BLUW vs DRTS Comparison

Compare BLUW & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLUW
  • DRTS
  • Stock Information
  • Founded
  • BLUW 2024
  • DRTS 2015
  • Country
  • BLUW United States
  • DRTS Israel
  • Employees
  • BLUW N/A
  • DRTS N/A
  • Industry
  • BLUW
  • DRTS Medical/Dental Instruments
  • Sector
  • BLUW
  • DRTS Health Care
  • Exchange
  • BLUW Nasdaq
  • DRTS Nasdaq
  • Market Cap
  • BLUW 322.1M
  • DRTS 300.2M
  • IPO Year
  • BLUW 2025
  • DRTS N/A
  • Fundamental
  • Price
  • BLUW $10.02
  • DRTS $4.20
  • Analyst Decision
  • BLUW
  • DRTS Strong Buy
  • Analyst Count
  • BLUW 0
  • DRTS 1
  • Target Price
  • BLUW N/A
  • DRTS $9.00
  • AVG Volume (30 Days)
  • BLUW 27.1K
  • DRTS 60.0K
  • Earning Date
  • BLUW 01-01-0001
  • DRTS 11-18-2025
  • Dividend Yield
  • BLUW N/A
  • DRTS N/A
  • EPS Growth
  • BLUW N/A
  • DRTS N/A
  • EPS
  • BLUW N/A
  • DRTS N/A
  • Revenue
  • BLUW N/A
  • DRTS N/A
  • Revenue This Year
  • BLUW N/A
  • DRTS N/A
  • Revenue Next Year
  • BLUW N/A
  • DRTS N/A
  • P/E Ratio
  • BLUW N/A
  • DRTS N/A
  • Revenue Growth
  • BLUW N/A
  • DRTS N/A
  • 52 Week Low
  • BLUW $9.93
  • DRTS $2.14
  • 52 Week High
  • BLUW $10.05
  • DRTS $4.69
  • Technical
  • Relative Strength Index (RSI)
  • BLUW N/A
  • DRTS 56.64
  • Support Level
  • BLUW N/A
  • DRTS $3.97
  • Resistance Level
  • BLUW N/A
  • DRTS $4.34
  • Average True Range (ATR)
  • BLUW 0.00
  • DRTS 0.28
  • MACD
  • BLUW 0.00
  • DRTS -0.01
  • Stochastic Oscillator
  • BLUW 0.00
  • DRTS 64.29

About BLUW Blue Water Acquisition Corp. III Class A Ordinary Shares

Blue Water Acquisition Corp III is a blank check company.

About DRTS Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.

Share on Social Networks: